Shenzhen Chipscreen Biosciences Co., Ltd. (Shanghai Stock Exchange STAR Market: 688321), the Chinese pharmaceutical developer specializing in epigenetic medicines and novel therapeutic mechanisms, announced on October 16, 2026, that China’s National Medical Products Administration has approved the Investigational New Drug application for NW001. The investigational medicine, co-developed with Chengdu Chipscreen Newway Biosciences, is an epigenetic immune-modulating antibody conjugate designed to deliver a histone deacetylase inhibitor through a PD-L1-targeted antibody. The authorization permits the company to proceed with a Phase 1 clinical trial in patients with advanced tumors.
The planned study will evaluate safety, tolerability, pharmacokinetics and preliminary antitumor activity, representing the first clinical development stage for a molecular approach that combines immune checkpoint targeting with intracellular epigenetic modulation. Chipscreen is investigating whether the conjugate can achieve meaningful activity in cancers that respond poorly to conventional PD-1 or PD-L1 blockade. The company says preclinical experiments demonstrated antitumor effects in checkpoint-resistant models and stronger activity than PD-L1 antibody treatment in selected responsive models.
NW001 differs from conventional antibody-drug conjugates because its payload is a histone deacetylase inhibitor, rather than a commonly used tubulin inhibitor or topoisomerase inhibitor. Histone deacetylase inhibition can affect gene expression and cellular signaling, potentially altering tumor biology and the surrounding immune environment. By linking this mechanism to a PD-L1 antibody, Chipscreen aims to concentrate epigenetic activity in PD-L1-expressing tissue while reducing exposure elsewhere.
However, the NMPA decision is authorization to conduct clinical research, not marketing approval. The company has not announced human dosing, objective tumor responses or a clinical safety dataset for NW001. Its claims of enhanced antitumor activity and improved tolerability remain based on laboratory and animal studies, making the forthcoming Phase 1 programme essential for evaluating the proposed therapeutic advantage.
Why is Chipscreen developing an antibody conjugate that targets PD-L1?
PD-L1 is a protein involved in immune regulation and is expressed by many tumor cells and cells within the tumor environment. Its interaction with the PD-1 receptor on T cells can suppress immune activity, providing one mechanism through which malignant cells evade immune recognition. Medicines blocking this interaction have become established treatment options across several cancers.
However, only a proportion of patients achieve durable benefit from checkpoint inhibition. Some tumors lack sufficient active immune-cell infiltration, while others develop resistance through changes in antigen presentation, inflammatory signaling or alternative immune-suppressive mechanisms. These challenges have encouraged research into treatments that influence more than one part of tumor biology.
NW001 uses a humanized anti-PD-L1 monoclonal antibody as a targeting component. The antibody is chemically connected to an epigenetic modulator intended to become available after the conjugate is internalized into cells. The strategy uses the presence of PD-L1 as a mechanism for directing treatment rather than relying exclusively on conventional checkpoint blockade.
The distinction is important because not every PD-L1-targeting antibody has identical biological activity. Binding to PD-L1 may support cellular delivery, but the contribution of direct checkpoint inhibition depends on the particular antibody’s binding and functional characteristics. Chipscreen has not disclosed detailed human evidence separating the effects of PD-L1 targeting from those of the released epigenetic payload.
The programme therefore seeks to address immunotherapy resistance through a combined delivery and pharmacological strategy. Its effectiveness will depend on whether sufficient drug reaches the appropriate tumor-associated cells and produces useful biological changes.
How does the HDAC inhibitor payload change the mechanism of NW001?
Histone deacetylases are enzymes involved in regulating chemical modifications of proteins, including histones associated with DNA packaging. By influencing the structure and activity of chromatin, these enzymes can affect which genes are expressed within a cell. Their biological roles extend into cell differentiation, proliferation, stress responses and immune signaling.
Histone deacetylase inhibitors can interfere with these processes and have demonstrated therapeutic activity in selected hematological malignancies and other diseases. However, systemic HDAC inhibition can also affect normal tissues because the enzymes participate in numerous physiological functions. This creates a challenge in achieving sufficient antitumor exposure without unacceptable adverse effects.
NW001 is designed to address that limitation through targeted delivery. Its antibody component binds cell-surface PD-L1, after which the conjugate is intended to enter the cell and release its HDAC inhibitor payload through intracellular cleavage. The company believes this could concentrate the epigenetic modulator within PD-L1-expressing tissue.
Unlike a conventional cytotoxic ADC, the intended benefit may involve changes in gene expression and immune regulation as well as direct effects on tumor-cell survival. That makes the proposed mechanism potentially broader but also more difficult to characterize. Different cancer types and immune populations may respond differently to the same HDAC inhibitor exposure.
The fundamental development question is whether the targeting strategy creates a sufficiently favorable therapeutic window. A conjugate that releases payload prematurely or accumulates in healthy PD-L1-expressing tissues could still produce systemic adverse effects. The intended selectivity must therefore be demonstrated experimentally and clinically.
What did the preclinical studies establish about checkpoint-resistant tumors?
Chipscreen reported that NW001 demonstrated meaningful antitumor activity in models that were insensitive or resistant to conventional PD-1 or PD-L1 checkpoint inhibition. The company also described greater activity than PD-L1 antibody treatment in selected models that remained responsive to checkpoint blockade. These findings support the hypothesis that the addition of epigenetic modulation may provide activity beyond that of a targeting antibody alone.
The experiments are particularly relevant because overcoming resistance remains an important objective in immuno-oncology. Tumors may develop mechanisms that prevent effective immune recognition despite checkpoint blockade. Altering gene expression or the immune environment could theoretically restore some sensitivity or influence malignant cells through additional pathways.
However, the October announcement does not disclose a complete numerical dataset describing tumor regression, animal survival or the number of models investigated. It also does not establish whether the results have been reproduced independently. Without those details, the magnitude and consistency of the reported improvement cannot be fully evaluated.
The company separately reported favorable pharmacokinetic characteristics and tolerability in non-human primate studies. These observations may support the clinical development package, but they do not prove safety in patients with advanced cancer. Drug distribution, metabolism and immune responses can differ considerably between species.
Preclinical studies provide a rationale for human testing rather than a definitive measure of therapeutic benefit. The ability to overcome resistance must be demonstrated through actual tumor responses in appropriately characterized patients.
Why is PD-L1-directed epigenetic delivery different from established ADC technology?
Most widely used oncology antibody-drug conjugates combine tumor-targeting antibodies with highly potent cytotoxic payloads. These may interfere with microtubules or DNA-processing enzymes, leading to direct cell injury after the payload is released. Their development depends on identifying a suitable tumor-associated antigen and controlling how the attached drug is delivered.
NW001 applies a similar structural concept to a different type of active molecule. Instead of relying primarily on a conventional cytotoxic payload, it carries a histone deacetylase inhibitor intended to influence epigenetic and immunological pathways. This creates a potential connection between targeted delivery and immune reprogramming.
The company describes the modality as an epigenetic immune-modulating antibody conjugate, or EIMAC. That classification reflects its proposed mechanism, although the term is not evidence of regulatory recognition as a superior class of medicine. The clinical properties will ultimately depend on the individual product.
A particular challenge concerns PD-L1 expression in normal immune and nonimmune tissues. The protein is not exclusive to malignant cells, and expression can vary with inflammatory conditions. Targeting PD-L1 therefore does not guarantee that the conjugate will accumulate only within tumors.
The linker and payload properties will also matter. Effective treatment requires adequate stability in circulation, cellular uptake, controlled release and sufficient intracellular exposure. The Phase 1 programme will begin evaluating whether these characteristics support an acceptable benefit-risk profile in humans.
How does NW001 build on Chipscreen’s experience with chidamide?
Chipscreen’s scientific background includes development of chidamide, marketed under the Epidaza brand in China. Chidamide is a subtype-selective histone deacetylase inhibitor that has received regulatory authorization for selected oncology indications. Its development established commercial and clinical experience within epigenetic drug research.
The company has subsequently investigated chidamide in combination with immunotherapies, seeking to determine whether epigenetic modulation can improve the effects of checkpoint inhibitors. Chipscreen says an international Phase 3 study involving chidamide and immune checkpoint treatment in melanoma has met its primary efficacy endpoint. It also reports completion of enrollment in a separate Phase 3 colorectal cancer study conducted in China.
These programmes provide scientific context for NW001 because they investigate the relationship between epigenetic regulation and antitumor immunity. However, using an approved HDAC inhibitor alongside checkpoint therapy is not the same as delivering a new HDAC inhibitor through an antibody conjugate. Differences in the drug, exposure pattern and target distribution can materially influence both efficacy and safety.
The company’s experience may support selection of biological endpoints and interpretation of pharmacodynamic findings. It may also inform the development of assays measuring changes in gene expression or immune-cell activity. Nevertheless, the clinical evidence generated with chidamide cannot be transferred directly to NW001.
NW001 must demonstrate its own pharmacological and clinical characteristics before the company can establish the value of the new formulation and targeting mechanism.
What role does Chipscreen Newway play in developing NW001?
NW001 is being co-developed with Chengdu Chipscreen Newway Biosciences, an associate company established as part of Chipscreen’s expansion into large-molecule drug development. Newway operates a research organization with more than 50 employees and approximately 3,000 square meters of laboratory space. Its technology portfolio includes antibody discovery, linker engineering and novel payload development.
The company has developed a platform combining multiple antibody discovery approaches with artificial intelligence-assisted protein engineering. It also operates its proprietary DSHL linker technology, designed for site-specific conjugation and control of drug-antibody ratio. These capabilities are relevant because antibody conjugates require consistent molecular structures and carefully controlled manufacturing characteristics.
Newway is also investigating other ADC strategies, including bispecific constructs and dual-payload medicines. The broader programme reflects an effort to differentiate beyond conventional combinations of one antibody target and one cytotoxic drug. However, the announced success of the NW001 regulatory application does not establish that every platform candidate is clinically effective.
The relationship gives Chipscreen access to expertise in biologics and antibody conjugation alongside its established small-molecule research capabilities. This integration may help the company develop medicines incorporating both targeted delivery and pharmacologically active molecules discovered through its epigenetics platform.
Chipscreen has not disclosed a separate transaction value or external licensing payment associated with the NW001 IND authorization. The October milestone concerns advancement of a jointly developed internal programme rather than a newly announced acquisition or third-party commercialization deal.
What will the authorized Phase 1 trial investigate in patients with advanced tumors?
The first clinical investigation will evaluate NW001 in patients with advanced malignancies, including tumor types where further treatment options are needed. According to the company, the study will focus on safety, tolerability, pharmacokinetics and preliminary antitumor activity. The announcement does not identify a final enrollment target, dosing schedule or specific list of participating hospitals.
Early clinical development will need to determine the amount of medicine that can be administered without unacceptable toxicity. Investigators will monitor adverse events, laboratory measurements and possible dose-limiting toxicities. Pharmacokinetic analysis will help establish how the intact conjugate and its components behave in circulation.
Potential immune-related and epigenetic effects will require particular attention. Although the intended delivery system may reduce broad exposure, HDAC inhibitor activity can influence multiple cellular pathways. The targeting antibody could also interact with PD-L1-expressing cells outside malignant tissue.
Exploratory antitumor measurements may include changes in tumor size, confirmed responses and duration of disease control. Such outcomes can provide early evidence of activity, but a Phase 1 study is not designed to establish comparative superiority over approved immunotherapies. Any responses would need to be interpreted according to dose, tumor type and prior treatment exposure.
The company has not announced that patients have already been dosed or that a recommended Phase 2 dose has been selected. IND authorization allows the programme to move toward clinical execution, but patient enrollment and treatment remain separate milestones.
What must NW001 demonstrate to justify a larger oncology programme?
The first requirement is establishing an acceptable safety profile while demonstrating that the conjugate delivers biologically active payload at clinically achievable exposures. The development team must determine whether tumor targeting produces a meaningful difference in drug distribution and whether the antibody-payload construct remains stable during circulation. These findings will help establish whether the proposed therapeutic window is realistic.
The next challenge is demonstrating evidence of antitumor activity in patients whose cancers have resisted previous treatment. Clear documentation of earlier PD-1 or PD-L1 exposure, tumor characteristics and response history will be important. Without appropriate patient classification, it may be difficult to establish whether NW001 is acting in genuinely checkpoint-resistant disease.
Biomarkers could also contribute to development decisions. PD-L1 expression, changes in epigenetic activity and immune-cell characteristics may help identify patients more likely to respond. However, an effective companion biomarker has not yet been validated for the medicine.
Further trials would then need to determine which cancer populations offer the clearest opportunity. A broad initial Phase 1 programme may identify signals across different tumors, but registration-directed development generally requires more defined patient populations and clinical endpoints. The company will also need to demonstrate consistent manufacturing of the antibody, linker and HDAC inhibitor components.
The NMPA’s October 2026 IND approval moves NW001 from preclinical research toward human evaluation and expands Chipscreen’s oncology pipeline into a differentiated antibody-conjugate modality. Its reported laboratory activity against immunotherapy-resistant tumors provides a rationale for development, while the company’s chidamide experience supports its interest in epigenetic immune modulation.
The decisive test is whether targeted HDAC inhibitor delivery can generate meaningful clinical responses without the systemic toxicity that may limit less selective approaches. Until patient data become available, NW001 remains an investigational medicine whose proposed ability to overcome checkpoint resistance and improve the therapeutic window has not been established in humans.
